论文部分内容阅读
目的探讨CHA2DS2-VASc评分法在非瓣膜性房颤患者卒中风险评估的作用。方法选择2010年12月-2011年12月我院门诊就诊或住院的非瓣膜性房颤患者234例,随机分成两组各117例,分别采用CHADS2评分法(对照组)及CHA2DS2-VASc评分法(观察组)进行卒中风险评估并给予预防性治疗,随访6个月,观察卒中的发生率。结果对照组卒中发生率7.69%,观察组卒中发生率1.71%,两组比较差异有统计学意义(P<0.05)。结论 CHA2DS2-VASc评分法较CHADS2评分法能更好地评估非瓣膜性房颤患者发生卒中的风险,采取预防措施,有效降低脑卒中的发生,值得临床推广应用。
Objective To investigate the role of CHA2DS2-VASc score in stroke risk assessment in patients with non-valvular atrial fibrillation. Methods A total of 234 patients with non-valvular atrial fibrillation (AFD) from December 2010 to December 2011 in our hospital were randomly divided into two groups (n = 117). The CHADS2 score (control group) and CHA2DS2-VASc score (Observation group) for stroke risk assessment and preventive treatment, followed up for 6 months to observe the incidence of stroke. Results The incidence of stroke in control group was 7.69%, and the incidence of stroke in observation group was 1.71%. The difference between the two groups was statistically significant (P <0.05). Conclusion The CHA2DS2-VASc score method can better assess the risk of stroke in patients with non-valvular atrial fibrillation than the CHADS2 score method. Preventive measures can be taken to effectively reduce the incidence of stroke, which is worthy of clinical application.